Copyright
©The Author(s) 2023.
World J Clin Cases. Jul 26, 2023; 11(21): 5083-5096
Published online Jul 26, 2023. doi: 10.12998/wjcc.v11.i21.5083
Published online Jul 26, 2023. doi: 10.12998/wjcc.v11.i21.5083
Figure 6 Influence of human umbilical cord-mesenchymal stem cell treatment on coagulation function.
Measurements for all indicators were taken at baseline and weeks 1, 2, 3, 4, 12, and 24 after the first infusion. A: Prothrombin time; B: Activated partial thrombokinase time; C: Thrombin coagulation time; D: Fibrinogen; E: D-dimer. aP < 0.05. Group I: Placebo group; Group II: Human umbilical cord-mesenchymal stem cell infusion group; PT: Prothrombin time; APTT: Activated partial thrombokinase time; TT: Thrombin coagulation time; FIB: Fibrinogen; D-D: D-dimer.
- Citation: Lian XF, Lu DH, Liu HL, Liu YJ, Yang Y, Lin Y, Xie F, Huang CH, Wu HM, Long AM, Hui CJ, Shi Y, Chen Y, Gao YF, Zhang F. Safety evaluation of human umbilical cord-mesenchymal stem cells in type 2 diabetes mellitus treatment: A phase 2 clinical trial. World J Clin Cases 2023; 11(21): 5083-5096
- URL: https://www.wjgnet.com/2307-8960/full/v11/i21/5083.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i21.5083